HEREDITARY ANGIOEDEMA - TYPE 1
Clinical trials for HEREDITARY ANGIOEDEMA - TYPE 1 explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA - TYPE 1 trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA - TYPE 1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot could stop dangerous swelling attacks in HAE
Disease control OngoingThis Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…
Matched conditions: HEREDITARY ANGIOEDEMA - TYPE 1
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HAE patients: experimental drug aims to slash attack rate
Disease control OngoingThis study tests an experimental drug called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug can reduce how often attacks happen over about 6 months. Participants must have had at least 2 att…
Matched conditions: HEREDITARY ANGIOEDEMA - TYPE 1
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief ENROLLING_BY_INVITATIONThis study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…
Matched conditions: HEREDITARY ANGIOEDEMA - TYPE 1
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC